Navigation Links
Accumetrics, Inc. Announces Endotech SPA as Exclusive Distributor for the VerifyNow System in Italy
Date:9/15/2009

SAN DIEGO, Sept. 15 /PRNewswire/ -- Accumetrics, Inc. announces today it has signed a new exclusive agreement with Endotech SPA for distribution of its VerifyNow(R) System in Italy. With the addition of Endotech to Accumetrics' growing number of distribution partners, Accumetrics now has local representation in 25 countries in Europe, Latin America and Asia / Pacific.

The VerifyNow System helps physicians assess patients' response to life-saving antiplatelet therapies, such as aspirin, Plavix(R), Effient (R), and GP IIb/IIIa inhibitors. As response to these drugs varies, the tests help physicians ensure their patients on antiplatelet medications are receiving the optimal benefit.

"We're pleased that Endotech will now oversee the Italian distribution of our VerifyNow System. The company's knowledge of the cardiology market in Italy is unparalleled," said Timothy I. Still, President and CEO of the Company. "Physicians worldwide have a need for the critical information that is provided by the VerifyNow System. We are enthusiastic about Endotech's ability to bring our value to the Italian market."

"We have already experienced significant interest in the VerifyNow System and look forward to the continued growth of our relationship with Accumetrics in the Italian market," said Aldo Pagani, President and CEO of Endotech SPA. "We believe that our understanding of the value the VerifyNow System brings to physicians coupled with our expertise in marketing and sales strategy in Italy will be the key to our mutual success."

About Accumetrics (www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient) and clopidogrel (Plavix)), and the GP IIb/IIIa inhibitors (e.g. ReoPro(R) and Integrilin(R)), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of sanofi-aventis. Effient is a registered trademark of Lilly-Daiichi Sankyo.

About Endotech SPA (www.endotech.it)

Endotech SPA is an Italian company distributing medical devices and equipment designed for cardiovascular physicians. The company specializes in the distribution and launch of innovative medical instrumentation technology and maintains a strong presence in the Italian market, offering optimized logistics and excellent technical and scientific support. Endotech SPA is UNI EN ISO 13485:2004 and 9001:2008 certified.

    CONTACT:
    Adam J. Handelsman
    Lippert/Heilshorn & Associates
    212-838-3777
    ahandelsman@lhai.com

    Timothy I. Still
    President and CEO
    Accumetrics
    858-404-8260
    press@accumetrics.com


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Accumetrics, Inc. Forms Partnership With Grifols as Its Distributor in Spain, Portugal and Chile
2. Accumetrics, Inc. Announces Distribution Channels in Israel and Cyprus
3. Accumetrics, Inc. Announces 1000th Patient Enrolled in GRAVITAS Trial
4. Accumetrics, Inc. Announces United Kingdom Distribution Agreement With ELITech UK Limited
5. Gregory J. Tibbitts Appointed Chief Financial Officer at Accumetrics, Inc.
6. Ad de Waard Appointed Vice President of International Sales and Marketing at Accumetrics, Inc.
7. Accumetrics, Inc. Appoints William Dippel as Executive Vice President of Operations and R&D
8. Caraco Pharmaceutical Laboratories, Ltd. Announces Appointment of F. Folsom Bell to Board of Directors
9. Advanced Life Sciences Announces Restanza(TM) Granted FDA Orphan Drug Designation for Plague and Tularemia
10. Accuray Announces Additions to Board of Directors
11. Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
Breaking Medicine Technology: